Zoe Biosciences is a biotechnology company committed to redefining healthspan by developing therapeutic solutions for ageing and age-related diseases. At the heart of its research is the study of a unique genetic mutation found in an Amish community in Indiana. This mutation, affecting the gene for PAI-1 (Plasminogen Activator Inhibitor-1), has been linked to extended lifespan and improved healthspan, offering protection against various ageing-related diseases. Zoe's approach is inspired by this "Amish Longevity Platform," leveraging these insights to develop drugs targeting PAI-1 and related pathways to delay ageing and promote healthier lives​.

The company's work is led by CEO Scott Gies, whose diverse background spans neuroscience, epigenetics, and longevity-focused ventures, and Chief Scientific Officer Dr. Douglas Vaughan, a leading expert on the molecular biology of ageing and PAI-1. Together, the team is advancing therapies that integrate cutting-edge science and the genetic advantages observed in this Amish population​